^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) +
    Empliciti (elotuzumab) (CS-1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    05/11/2016
    Excerpt:
    Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in...combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …the NCCN Panel has included elotuzumab in combination with lenalidomide and dexamethasone as a category 1 option for previously treated MM.
    Secondary therapy:
    dexamethasone